Mersana Therapeutics (MRSN) Misses Q2 EPS by $4.71

Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($4.87), $4.71 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.06 million versus the consensus estimate of $6.25 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• Saudi Arabia shuts East-West Pipeline after attacks